EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients

Ulrik Fahnøe iD, Lone Wulff Madsen, Peer Brehm Christensen, Christina Søhoel Sølund, Sarah Mollerup iD, Mette Pinholt, Nina Weis, Anne Øvrehus, Jens Bukh iD

Microbiology Spectrum · 03.09.2024 · 12 (9)

DOI: 10.1128/spectrum.00641-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.09.2024. Verfasst von Ulrik Fahnøe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Benzimidazoles, Sofosbuvir. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coinfections with human pegivirus 1 (HPgV-1) are common in chronic hepatitis C virus (HCV) patients. However, little is known about whether HPgV-1 is affected by direct-acting antivirals during HCV treatment. Metagenomic analysis and reverse transcriptase-quantitative PCR (RT-qPCR) were performed on RNA from the plasma of 88 selected chronic HCV patients undergoing medical treatment. Twenty (23%) of these HCV patients had HPgV-1 coinfections and were followed by RT-qPCR during treatment and follow-up to investigate HPgV-1 RNA titers. Recovered sequences could be assembled to complete HPgV-1 genomes, and most formed a genotype 2 subclade. All HPgV-1 viral genomic regions were under negative purifying selection. Glecaprevir/pibrentasvir treatment in five patients did not consistently lower the genome titers of HPgV-1. In contrast, a one log 10 drop of HPgV-1 titers at week 2 was observed in 10 patients during treatment with sofosbuvir-containing regimens, sustained to the end of treatment (EOT) and in two cases decreasing to below the detection limit of the assay. For the five patients treated with ledipasvir/sofosbuvir with the inclusion of pegylated interferon, titers decreased to below the detection limit at week 2 and remained undetectable to EOT. Subsequently, the HPgV-1 titer rebounded to pretreatment levels for all patients. In conclusion, we found that HCV treatment regimens that included the polymerase inhibitor sofosbuvir resulted in decreases in HPgV-1 titers, and the addition of pegylated interferon increased the effect on patients with coinfections. This points to the high specificity of protease and NS5A inhibitors toward HCV and the more broad-spectrum activity of sofosbuvir and especially pegylated interferon. IMPORTANCE Human pegivirus 1 coinfections are common in hepatitis C virus (HCV) patients, persisting for years. However, little is known about how pegivirus coinfections are affected by treatment with pangenotypic direct-acting antivirals (DAAs) against HCV. We identified human pegivirus by metagenomic analysis of chronic HCV patients undergoing protease, NS5A, and polymerase inhibitor treatment, in some patients with the addition of pegylated interferon, and followed viral kinetics of both viruses to investigate treatment effects. Only during HCV DAA treatment regimens that included the more broad-spectrum drug sofosbuvir could we detect a consistent decline in pegivirus titers that, however, rebounded to pretreatment levels after treatment cessation. The addition of pegylated interferon gave the highest effect with pegivirus titers decreasing to below the assay detection limit, but without clearance. These results reveal the limited effect of frontline HCV drugs on the closest related human virus, but sofosbuvir appeared to have the potential to be repurposed for other viral diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis C, ChronicBenzimidazolesSofosbuvirPegivirusCoinfectionFlaviviridae InfectionsHumansMaleFemaleGenotypeQuinoxalinesMiddle AgedPyrrolidinesSulfonamidesRNA, ViralHepacivirusGenome, ViralAdultAgedViral LoadMetagenomicsCyclopropanesAminoisobutyric AcidsPhylogenyDrug Combinations

Stichwörter der Autor:innen

DAAHCVHPgV-1coinfectiondirect-acting antiviralshepatitis C virushuman pegivirusmetagenomicspegylated interferonsofosbuvir

Substanzen

Antiviral AgentsBenzimidazolesSofosbuvirQuinoxalinesPyrrolidinesSulfonamidesRNA, ViralCyclopropanesglecaprevir and pibrentasvirAminoisobutyric Acids

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
  • Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
  • Institute for Regional Health Research, University of Southern Denmark, Research Unit for Internal Medicine Kolding Hospital, Kolding, Denmark.
  • Clinical Institute, University of Southern Denmark, Odense, Denmark.
  • Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.

ORCID-Profile: Ulrik Fahnøe, Sarah Mollerup, Jens Bukh

Zitieren

APA

Fahnøe, U., Madsen, L. W., Christensen, P. B., Sølund, C. S., Mollerup, S., Pinholt, M., Weis, N., Øvrehus, A., & Bukh, J. (2024). Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients. Microbiology Spectrum, 12(9). https://doi.org/10.1128/spectrum.00641-24

Vancouver

Fahnøe U, Madsen LW, Christensen PB, Sølund CS, Mollerup S, Pinholt M, et al. Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients. Microbiology Spectrum. 2024;12(9). doi:10.1128/spectrum.00641-24

BibTeX
@article{Fahne2024,
  author = {Fahnøe, Ulrik and Madsen, Lone Wulff and Christensen, Peer Brehm and Sølund, Christina Søhoel and Mollerup, Sarah and Pinholt, Mette and Weis, Nina and Øvrehus, Anne and Bukh, Jens},
  title = {Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {9},
  doi = {10.1128/spectrum.00641-24}
}
Kostenlos starten →